Horizon Kinetics Asset Management LLC Purchases 121 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Horizon Kinetics Asset Management LLC grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,880 shares of the biopharmaceutical company’s stock after buying an additional 121 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $678,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of ALNY. Huntington National Bank raised its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Larson Financial Group LLC raised its stake in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Finally, True Wealth Design LLC raised its stake in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 4.7 %

NASDAQ:ALNY opened at $253.11 on Tuesday. The firm’s fifty day moving average is $255.57 and its 200-day moving average is $259.72. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a market cap of $32.77 billion, a P/E ratio of -116.64 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ALNY has been the subject of several analyst reports. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Piper Sandler restated an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.